Journal
ARCHIVES OF NEUROLOGY
Volume 60, Issue 9, Pages 1202-1206Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/archneur.60.9.1202
Keywords
-
Categories
Ask authors/readers for more resources
Background: The antemortem diagnosis of Alzheimer disease (AD) requires time-consuming and costly procedures. Therefore, biochemical tests that can direct the physician rapidly to the correct diagnosis are highly desirable. Measurement of single biochemical markers in cerebrospinal fluid (CSF), such as total tau protein and beta-amyloid peptide(42) (Abeta(42)), shows robust alterations that highly correlate with the clinical diagnosis of AD but generally lack sufficient diagnostic accuracy. Objective: To study the combination of CSF phosphorylated tau protein (phospho-tau) and Abeta(42), as biochemical markers for AD. Methods: We combined CSF measurements of phosphotau and Abeta(42) in 100 consecutive patients who underwent diagnostic workup for dementia and in 31 healthy control subjects. Results: We found that the calculated ratio of phosphotau to Abeta(42) was significantly increased in patients with AD and provided high diagnostic accuracy in distinguishing patients with AD from healthy control subjects (sensitivity, 86%; specificity, 97%), subjects with non-AD dementias (sensitivity, 80%; specificity, 73%), and subjects with other neurological disorders (sensitivity, 80%; specificity, 89%). Conclusion: The diagnostic usefulness of the CSF ratio of phospho-tau to Abeta(42) is superior to either measure alone and can be recommended as an aid to evaluating individuals suspected of having dementia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available